Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4182554)

Published in PLoS One on September 30, 2014

Authors

Zhi-Peng Xu1, Li Li1, Jian Bao1, Zhi-Hao Wang1, Juan Zeng1, En-Jie Liu1, Xiao-Guang Li1, Rong-Xi Huang1, Di Gao1, Meng-Zhu Li1, Yao Zhang2, Gong-Ping Liu1, Jian-Zhi Wang1

Author Affiliations

1: Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Neurological Disease of National Education Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2: Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Li Yuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Articles cited by this

A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13

Long-term potentiation and memory. Physiol Rev (2004) 4.98

Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55

Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci (2010) 3.65

Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30

Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61

Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci (2011) 2.47

Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care (2004) 2.24

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24

Enhancement of synaptic plasticity through chronically reduced Ca2+ flux during uncorrelated activity. Neuron (2004) 2.21

Rapid spine stabilization and synaptic enhancement at the onset of behavioural learning. Nature (2010) 2.08

Enhancement of learning and memory by elevating brain magnesium. Neuron (2010) 2.00

Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97

Preventing Alzheimer's disease. Science (2012) 1.94

Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol (2011) 1.92

Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol (2008) 1.91

TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. Nat Neurosci (2012) 1.82

Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med (2005) 1.78

Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol (2008) 1.74

Role of magnesium in genomic stability. Mutat Res (2001) 1.69

Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci (1998) 1.56

Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes (2007) 1.48

Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid Redox Signal (2012) 1.32

Hippocampal synaptic plasticity, spatial memory and anxiety. Nat Rev Neurosci (2014) 1.31

The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol (2002) 1.29

Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry (2010) 1.24

Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem (2006) 1.23

The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev (2009) 1.22

Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21

A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology (2013) 1.21

The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol (2004) 1.19

Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis (2009) 1.16

Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport (2004) 1.15

Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol (2010) 1.02

Measuring brain manganese and iron accumulation in rats following 14 weeks of low-dose manganese treatment using atomic absorption spectroscopy and magnetic resonance imaging. Toxicol Sci (2008) 1.02

Magnesium metabolism: a review. J Clin Chem Clin Biochem (1980) 0.99

Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol (2010) 0.93

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol (2014) 0.92

Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep (2008) 0.92

Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem (2013) 0.90

Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis (2012) 0.90

Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. Neurotoxicology (2013) 0.89

Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol (2012) 0.88

Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis (2009) 0.88

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement (2014) 0.88

A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol (2011) 0.87

Altered ionized magnesium levels in mild-to-moderate Alzheimer's disease. Magnes Res (2011) 0.86

The biochemical function of Mg²+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes Res (2010) 0.86

Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities. Trends Pharmacol Sci (1992) 0.86

Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J Alzheimers Dis (2011) 0.84

Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res (2011) 0.84

Retracted Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. J Neurosci (2013) 0.83

Acetyl-L-carnitine rescues scopolamine-induced memory deficits by restoring insulin-like growth factor II via decreasing p53 oxidation. Neuropharmacology (2013) 0.83

Magnesium depletion and pathogenesis of Alzheimer's disease. Magnes Res (1990) 0.83

Effects of corticosterone and amyloid-beta on proteins essential for synaptic function: implications for depression and Alzheimer's disease. Biochim Biophys Acta (2013) 0.82

Streptozotocin-induced sporadic Alzheimer's disease: selection of appropriate dose. J Alzheimers Dis (2013) 0.81

Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease. Magnes Res (2000) 0.81

Magnesium modulates amyloid-beta protein precursor trafficking and processing. J Alzheimers Dis (2010) 0.81

New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opin Ther Targets (2013) 0.80

Phosphoinositide 3-kinase/Akt pathway is involved in mediating the anti-inflammation effects of magnesium sulfate. J Surg Res (2013) 0.80

Magnesium deficiency impairs fear conditioning in mice. Brain Res (2005) 0.80

Agmatine protects against intracerebroventricular streptozotocin-induced water maze memory deficit, hippocampal apoptosis and Akt/GSK3β signaling disruption. Eur J Pharmacol (2014) 0.77

Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology (Berl) (2014) 0.76

Chronically elevating plasma Mg2+ improves hippocampal frequency potentiation and reversal learning in aged and young rats. Brain Res (1984) 0.76